SWOG clinical trial number
S9714

A Phase II Trial of Paclitaxel by 96-Hour Infusion in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Taxol in Stage IIIB & IV BAC
Activated
05/15/1997
Closed
03/15/2000

Research committees

Lung Cancer

Publication Information Expand/Collapse

2005

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.

HL West;JJ Crowley;RB Vance;WA Franklin;RB Livingston;SR Dakhil;JK Giguere;SE Rivkin;MJ Kraut;K Chansky;DR Gandara Annals of Oncology 16:1076-1080

2004

Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition

DR Gandara;H West;K Chansky;AM Davies;DHM Lau;J Crowley;PH Gumerlock;FR Hirsh;WA Franklin Clinical Cancer Research 10 (Suppl):4205s-4209s

2003

EGFR, HER2 and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC): analysis of SWOG 9417 and lung spore tissue samples.

WA Franklin;PH Gumerlock;J Crowley;K Chansky;HJ West;DR Gandara Proc of the American Society of Clinical Oncology 22:620(#2493)

2001

A phase II Southwest Oncology Group trial (S9714) utilizing paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma of the lung (BAC).

RB Vance;JJ Crowley;RB Livingston;DR Gandara Proc of the American Society of Clinical Oncology 20:336a(#1340)

2000

Phase II evaluation of paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma (BAC)

RB Vance;JJ Crowley;D Gandara Lung Cancer 29(Suppl.2):7(#16)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A082304/S2402

Perioperative Versus Adjuvant Systemic Therapy In Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG, CTIU2317
Research Committee(s)
Lung Cancer
Activated
12/11/2024
Open